Cargando…
Successful Re-administration of Atezolizumab for a Non-small-cell Lung Cancer Patient after Cardiac Tamponade Development as a Manifestation of Pseudo-progression Induced by Combination Treatment with Atezolizumab and Cytotoxic Chemotherapy
Pseudo-progression is a phenomenon induced by treatment with immune checkpoint inhibitors and is characterized by an increase in tumor size or the appearance of new lesions, followed by tumor regression. However, life-threatening conditions, such as cardiac tamponade, can develop in such patients. W...
Autores principales: | Nakashima, Koki, Demura, Yoshiki, Sato, Masayuki, Fujii, Yuya, Igarashi, Kazunari, Ishizuka, Tamotsu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502658/ https://www.ncbi.nlm.nih.gov/pubmed/33814492 http://dx.doi.org/10.2169/internalmedicine.6509-20 |
Ejemplares similares
-
Long-Term Survival With Pembrolizumab Re-administration After Pseudo-Progression With Immune-Related Interstitial Lung Disease in a Patient With Non-small Cell Lung Cancer
por: Nakashima, Koki, et al.
Publicado: (2021) -
Immune Checkpoint Inhibitor-Induced Limbic Encephalitis during Treatment with Atezolizumab in a Patient with Small-Cell Lung Cancer: A Case Report and Review of the Literature
por: Nakashima, Koki, et al.
Publicado: (2022) -
Malignant pericardial effusion complicated by cardiac tamponade under
atezolizumab
por: Benjamin, Lardinois, et al.
Publicado: (2021) -
A case of non-small cell lung cancer presenting anti-amphiphysin antibody-positive paraneoplastic neurological syndrome
por: Nakashima, Koki, et al.
Publicado: (2021) -
Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer
por: Tsuda, Takeshi, et al.
Publicado: (2023)